Citius Pharmaceuticals, Inc.: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Citius Pharmaceuticals, Inc. listata cu simbolul US.CTXR ==Descriere companie== Citius Pharmaceuticals Inc. (www.citiuspharma.com) is a specialty pharmaceutical company. The Company is focused on development of critical care products, such as anti-infective products in adjunct cancer care, prescription products and stem cell therapy. The Company has three products: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Citius Pharmaceuticals Inc. (www.citiuspharma.com) is a specialty pharmaceutical company. The Company is focused on development of critical care products, such as anti-infective products in adjunct cancer care, prescription products and stem cell therapy. The Company has three products: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CITI-002 helps to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap product (CITI-101) is a malleable, bio-absorbable film impregnated with minocycline and rifampin. It is designed to reduce infections associated with the use of breast tissue expanders (TE) used in breast reconstruction surgeries following mastectomies. | Citius Pharmaceuticals Inc. (www.citiuspharma.com) is a specialty pharmaceutical company. The Company is focused on development of critical care products, such as anti-infective products in adjunct cancer care, prescription products and stem cell therapy. The Company has three products: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CITI-002 helps to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap product (CITI-101) is a malleable, [[BIO|bio]]-absorbable film impregnated with minocycline and rifampin. It is designed to reduce infections associated with the use of breast tissue expanders (TE) used in breast reconstruction surgeries following mastectomies. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 25 noiembrie 2024 05:16
Pagina dedicata companiei Citius Pharmaceuticals, Inc. listata cu simbolul US.CTXR
Descriere companie[edit | ]
Citius Pharmaceuticals Inc. (www.citiuspharma.com) is a specialty pharmaceutical company. The Company is focused on development of critical care products, such as anti-infective products in adjunct cancer care, prescription products and stem cell therapy. The Company has three products: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CITI-002 helps to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap product (CITI-101) is a malleable, bio-absorbable film impregnated with minocycline and rifampin. It is designed to reduce infections associated with the use of breast tissue expanders (TE) used in breast reconstruction surgeries following mastectomies.
Grafic actiuni companie[edit | ]